| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 31.5 | 30.2 |
| Net income | 2.7 | 63.9 |
| EPS (diluted, $ a share) | $0.02 | $1.94 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -95.7% |
|---|---|
| Revenue, year on year | +4.1% |
| Operating margin | 36.2% |
10-Q filed with the SEC, NASDAQ: AGEN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Agenus Inc: key numbers
- Share price
- $6.29Close, Nov 16
- Market cap
- $285M
- Shares outstanding
- 45.25MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Agenus Inc
All →Agenus Financial Results
Agenus reported third-quarter 2026 financial results, achieving its third consecutive quarter of positive operating income and ending the period with $86.9 million in cash. The company highlighted the first marketing authorizations for its BOT+BAL combination in Armenia and confirmed its Phase 3 ROBBIN study in MSS colon cancer is on track for first patient enrollment in Q1 2027.
“We have moved beyond planning ROBBIN to mobilizing investigators and activating sites around the world in preparation for patient enrollment. The strong investigator engagement in Madrid and São Paulo, together with the peer-reviewed NEST and UNICORN publications, strengthens our confidence in the potential of BOT+BAL to change outcomes for patients with MSS colon cancer. We have a clear registrational path and financing aligned with our milestones to support our operations through 2031.”
Garo H. Armen, Ph.D., Chairman and Chief Executive Officer of Agenus